Phase 3 N=120 Efficacy and Safety Evaluation in Recurrent Wheezing Attacks
Bronchospasm; Bronchiolitis · Bronchospasm; Bronchitis
Primary: Number of Recurrent Bronchospasm (Wheezing Attacks) — 299; 176 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=62 Montelukast for Early Life Wheezing
Lung Diseases · Asthma
Primary: Number of Wheezing-free Days of Infant (Observed by Primary Caregiver) — 25.5; 30.5 Days
Phase 2 N=60 Preschool Wheeze: Inflammation/Infection Guided Management
Asthma
Primary: Number of Unscheduled Healthcare Visits (UHCV) — 0.5; 0.5 number of visits — p=0.05
Phase 3 N=200 Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II
Respiratory Syncytial Virus, Bronchiolitis
Primary: Number of Participants Who Experienced the Occurrence of a Third Episode of Post-RSV Wheezing (Recurrent Wheeze) — 45; 33 Participants — p=0.08
Phase 4 N=80 Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing
Asthma
Primary: Mean Rate of Wheezing Attacks — 3.57; 5.72 wheezing attacks/per patient — p=0.05
N/A N=118 Using Tests in Preschool Children With Wheeze to Determine the Need for Inhaled Corticosteroid Therapy.
Wheezing
Primary: Wheeze Attacks — 1 Wheeze attacks
Phase 2 N=40 Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis
RSV Bronchiolitis
Primary: IL-8 Concentrations — 12,795; 14,676 Pg/ml — p=0.6
Phase 4 N=300 Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy
Wheezing · Allergy
Primary: Number of Infants With Recurrent Wheezing — 42; 56 Participants — p=0.02
Phase 3 N=278 CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)
Asthma
Primary: Rate of Exacerbations Requiring Systemic Corticosteroids — 0.97; 0.95 events per years of follow-up
N/A N=59 Modulation Of Airway Reactivity With Chronic Mechanical Strain
Asthma
Primary: Change in Airway Reactivity From Baseline (Visit 1) and 4 Weeks (Visit 2) — 3.0; 3.2; 5.3; 4.3 mg/mL
Phase 4 N=10 Dose-Response of Salmeterol in Children
Asthma
Primary: Total Airway Resistance Increase — 47; 22.9 ln(mg/mL)
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
Phase 2 N=18 PEEP as Rescue Therapy for Asthmatics With Elevated BMI
Asthma
Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L
N/A N=126 The Natural History of Small Airways Physiology in Diseased and Healthy States
Asthma · COPD · Interstitial Lung Disease
Primary: FEV1 — 3.03; 2.32; 3.18; 2.76 L
N/A N=119 Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes
Asthma · Children
Primary: Hospital Admission — 11; 8 participants — p=0.689
Phase 4 N=61 Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children
Asthma
Primary: Wheezing/Asthma/Bronchospasm Relapse Rate — 8.7; 4.0 percentage of cases of asthma relapse
Phase 4 N=66 The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)
Exercise-induced Bronchoconstriction (EIB)
Primary: Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Postdose — 15.35; 20.00 Percent fall in FEV1 — p=0.020
N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
N/A N=60 Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street
Asthma
Primary: Spirometry, Percentage Change in FEV1 From Baseline — -1.0; -4.8; -2.2; -7.4 percentage change in FEV1 from baseline — p=<0.05
Phase 4 N=52 Role of Pepsin Assay in Wheezy Infants
Gastroesophageal Reflux Disease
Primary: Number of Participants in Each Level of Wheeze Control — 18; 11; 9 Participants
N/A N=64 Breathing Retraining for Asthma Trial of Home Exercises for Teenagers
Adolescent Behavior · Asthma
Primary: Asthma-specific Quality of Life — 65.4; 65.1; 66.7; 67.4 score on a scale
Phase 1 N=17 A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma
Wheezing · Reactive Airway Disease · Mild Asthma
Primary: AUClast of Plasma Budesonide (VR647 Inhalation Suspension Delivered by the VR647 Inhalation System or Pulmicort Respules Delivered by a Conventional Jet Nebulizer)…
N/A N=7 Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma · Atopy
Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage
Phase 2 N=49 Oxidative Stress in Asthma
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
Phase 2 N=12 Treating Respiratory Emergencies in Children Study
Asthma in Children
Primary: Proportion of Patients Admitted to the Hospital in Each Group — 6; 15 Participants
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
Phase 2 N=54 Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Participants Who Completed Follow up — 35; 17 Participants
N/A N=1,283 Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants
N/A N=43 HFCWO in Hospitalized Asthmatic Children
Bronchial Asthma · Asthma · Status Asthmaticus
Primary: The Primary Endpoint Will be Time to Readiness for Discharge. — 1.74; 1.75 days